Industries Study Report: Antibodies Industry

Showing posts with label Antibodies Industry. Show all posts

Analyzing the Strengths, Weaknesses, Opportunities, and Threats in the Antibodies Industry

Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, and Segment Forecasts, 2023 - 2030

The global Antibodies Industry is anticipated to increase at a significant CAGR from 2023 to 2030.

Grand View Research’s antibodies industry data book is a collection of market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the data book, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.

Antibody Production Market Insights

The global antibody production market size was valued at USD 16.35 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.92% from 2023 to 2030. Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, coupled with the growing demand for therapeutic antibodies, has led to the rapid growth of the market. The COVID-19 pandemic has had a significant impact on the market. With the urgent need for therapeutic antibodies and vaccines to combat the virus, there has been a surge in demand for antibody production services.

Increasing investment in research and development of monoclonal antibodies is expected to drive market growth, especially in cancer treatment, which accounts for almost 50% of all R&D programs related to mAbs. The targeted approach of mAbs has revolutionized cancer treatment by reducing side effects and improving patient outcomes. Despite this, ongoing research and development are necessary to optimize mAb efficacy in cancer treatment. A significant milestone in the field of mAb therapeutics is the recent approval, by the European Commission of Bristol Myers Squibb’s combination therapy of Yervoy and OPDIVO for treating malignant pleural mesothelioma in June 2021. This approval highlights the potential of mAbs in treating complex and severe diseases and reinforces the need for continued investment in the research and development of mAb therapeutics.

Order your copy of the Free Sample of “Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Monoclonal Antibodies Market, by Application, 2020 - 2030 (USD Billion)

Monoclonal Antibodies Market Insights

The global monoclonal antibodies market size was valued at USD 210.06 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 11.04% from 2023 to 2030. Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others are increasing the demand for biologics, which is anticipated to serve as a key factor driving the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies and rising awareness about such therapies amongst patients and physicians is expected to significantly contribute toward the market growth.

The market is also favored by the strategic initiatives undertaken by key players for the development and marketing of mAb products. For instance, in October 2021, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB for the production and supply of CT83 mAbs. Similarly, in January 2022, Ono Pharmaceutical Co., Ltd. and Neurimmune AG collaborated on the creation of mAb drugs against new therapeutic targets for neurodegenerative diseases. Such initiatives are expected to open new growth opportunities and positively affect market growth.

However, high costs associated with the development of mAbs and the resultant increase in prices for mAb therapeutics can impede market growth in the near future. For instance, COVID-19 treatment mAbs such as Regeneron’s REGEN-COV (casirivimab and imdevimab), and GlaxoSmithKline & Vir Biotechnology’s sotrovimab cost around USD 1,250 and USD 2,100 per infusion, respectively. Such high drug prices can limit the access to mAb therapies for the large patient populations in developing countries and restrict mAbs adoption.

Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study

Antibodies Industry Data Book Competitive Landscape

To maintain a significant share in the market, key participants are undertaking various initiatives and implementing business strategies, such as product launches, product portfolio expansion, reinforcement and stabilizing the distribution network, and manufacturing capacity expansion and geographic reach expansion through acquisitions, collaborations, and partnerships.

Key players operating in the Antibodies Industry are:

Danaher Corporation
Sartorius AG
Thermo Fisher Scientific, Inc.
GE Healthcare
Merck KGaA

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
Follow Us: LinkedIn | Twitter

Antibodies Industry: List of Key Distributors and Channel Partners

Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Polyclonal Antibodies Market Growth & Trends

The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests.

The use of polyclonal antibodies has had a positive impact on the treatment of COVID-19 patients, with studies showing that these therapies can reduce hospitalization rates and improve outcomes for patients with mild to moderate disease. Additionally, the development of pAbs has helped to advance the understanding of the immune response to COVID-19 and is projected to lead the development of more effective treatments and vaccines in the future. Thus, the COVID-19 pandemic has had a significant impact on the pAbs market.

Several government initiatives support and promote the development and use of polyclonal antibodies in various applications, including diagnostics, therapeutics, and research. These initiatives are aimed at improving healthcare outcomes, promoting innovation, and supporting the growth of the biotechnology and pharmaceutical industries. Moreover, many governments are also taking initiatives to promote collaborations between academic institutions, research organizations, and industry players in the pAbs market. For instance, in May 2020, the Canadian Government invested USD 175 million in AbCellera, to support the organization in its antibody treatment examination and the production of the antibody construction facility. Thus, such various government initiatives are anticipated to increase the demand for the pAbs market.

Cancer Monoclonal Antibodies Market Growth & Trends

The global cancer monoclonal antibodies market size is expected to reach USD 281.78 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.18% from 2023 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.

Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage and scope of the study

Competitive Landscape

Key players operating in the Antibodies industry are:

Eppendorf AG
Cellab GmbH
INTEGRA Biosciences AG
Novartis AG
Pfizer Inc.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Antibodies Industry Revenue is driven by Rise in The Availability of Technologically Advanced Products

Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, and Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, and Segment Forecasts, 2023 - 2030

Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like trade data, pricing intelligence, and competitive benchmarking.

Antibody Production Market Report Highlights

The global antibody production market size was valued at USD 16.35 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.92% from 2023 to 2030.

Based on product, the consumables segment dominated in terms of the revenue share of 55.93% in 2022. This is attributed to growing demand for antibodies for study, diagnostics, and therapeutics, which has steered to a corresponding rise in the demand for consumables
Based on process, the downstream segment dominated in terms of the revenue share of 67.04% in 2022 owing to the various technological advancements supporting the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing, and hence, increasing the demand for the process in the antibody production market
In 2022, North America dominated with a revenue share of 38.29%, owing to the rising investments in drug discovery, growing developments in biopharmaceutical research, and the presence of major key players are anticipated to drive the growth of the antibody production market in this region
Asia Pacific accounted for the fastest-growing region with a CAGR of 16.13% from 2023 to 2030. The growing investments in R&D activities and the increasing prevalence of chronic diseases are driving the rising demand for the antibody production market in this region

Antibody Production Market Share, by Product, 2022 (%)

Monoclonal Antibodies Market Report Highlights

The global monoclonal antibodies market size was valued at USD 210.05 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 11.04% from 2023 to 2030.

By source type, the human mAbs segment held the largest share of 54.3% in 2022 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies
In vitro production type held a dominating share of 76.9% in 2022 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities
The oncology segment dominated the market in 2022 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies
Hospitals accounted for the largest share of the end-use segment in 2022 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics
North America accounted for 46.1% of the market value in 2022 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others
The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.

Order your copy of Free Sample of “Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, and Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Research Antibodies Market Report Highlights

The global research antibodies market size was valued at USD 1.5 billion in 2022 and is expected to grow at compound annual growth rate (CAGR) of 4.76% from 2023 to 2030.

In 2022, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies
By type, monoclonal antibodies captured a substantial share in 2022 due to the increase in COVID-19-related research activities involving the use of such antibodies
The western blotting technology segment held a dominant share of over 29.57% in 2022 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies
By end-use, academic and research institutions held the largest share of over 61.17% in 2022 due to a rise in funding opportunities and growth in the number of scientific institutions involved in life sciences
In 2022, North America accounted for the largest share of over 39.15% due to the widespread presence of life sciences research institutions and numerous biotechnology and biopharmaceutical manufacturers in the region

Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study

Competitive Landscape

Key players operating in the Antibodies industry are:

Danaher Corporation
Thermo Fisher Scientific Inc.
Sartorius AG
GE Healthcare
Eppendorf AG
Merck KGaA

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Analyzing the Strengths, Weaknesses, Opportunities, and Threats in the Antibodies Industry

Antibodies Industry: List of Key Distributors and Channel Partners

Antibodies Industry Revenue is driven by Rise in The Availability of Technologically Advanced Products

Inside the Unified Endpoint Management Market: Where AI Meets Zero Trust Endpoint Security